@article{5a84478b888a43659eb5bd132e404954,
title = "Lorlatinib: a new-generation drug for ALK-positive NSCLC",
author = "Waqar, {Saiama N.} and Daniel Morgensztern",
note = "Funding Information: SW reports grants from 1 UM1 CA186704-01 and has been the institutional principal investigator for studies from F Hoffmann-La Roche, Ariad, Pfizer Pharmaceuticals, Hengrui Therapeutics, Xcovery, EMD Serono Research & Development Institute, Checkpoint Therapeutics, Genentech, Lilly, Stemcentrx, Ignyta, Bristol-Myers Squibb Pharmaceutical, Synermore Biologics Co, Novartis Pharmaceuticals Corporation, Merck & Company, and NewLink Genetics Corporation, outside the submitted work. DM reports personal fees from Celgene, Bristol-Myers Squibb, AbbVie, Roche, and Heat Biologics; and has been the institutional principal investigator for studies from Celgene, Bristol-Myers Squibb, Abbvie, Roche, Heat Biologics, Incyte, Astra-Zeneca, Epicentrx, Novartis, Jansen, and Ignyta, outside the submitted work.",
year = "2018",
month = dec,
doi = "10.1016/S1470-2045(18)30789-7",
language = "English",
volume = "19",
pages = "1555--1557",
journal = "The Lancet Oncology",
issn = "1470-2045",
number = "12",
}